Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zivo Bioscience, Inc.ZIVO · Entity 9611 | Director · President and CEO | January 26, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zivo Bioscience, Inc.
Report date January 26, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,618 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Purchase · Acquired 11,709 · Balance 19,618 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nexvet Biopharma plc
Report date July 31, 2017 · Filed August 02, 2017
Section 16 reporting ended · disclosed 2017-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 1
1 source rowRow 1 · 2017-07-31 · Disposition to issuer · Disposed 10,800 · Balance 0 F1: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer. |
| Ordinary SharesSEC Table I · non-derivative | IndirectJohn B. Payne Living A/C | 0 |
Reported balance
After 2017-07-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-07-31 · Disposition to issuer · Disposed 6,195 · Balance 0 F1: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer. F2: The reporting person has sole voting and dispositive power with respect to these reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
F2: The reporting person has sole voting and dispositive power with respect to these reported securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 28, 2026 21:06 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 11,709 | $8.54 | $99,994.86 |
DisclosureSEC source: 0001654954-26-000651 · section16.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,618 Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 20:07 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Warrant · Derivative | 634 | $15.77 Strike: $15.77 | $9,995.01 |
DisclosureSEC source: 0001654954-24-013034 · section16.xml · derivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634 Underlying: Common Stock · 634 shares Expires 2029-10-15 Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 20:07 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 6,343 | $15.76 | $99,965.68 |
DisclosureSEC source: 0001654954-24-013034 · section16.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,909 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 50,251 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001654954-24-007460 · section16.xml · derivative · entry 5 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,251 Underlying: Common Stock · 50,251 shares Expires 2034-06-04 F4 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 167,180 | Not disclosed Strike: $7.96 | Not disclosed |
DisclosureSEC source: 0001654954-24-007460 · section16.xml · derivative · entry 4 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,180 Underlying: Common Stock · 167,180 shares Expires 2034-06-04 F3 · price: The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96. F4 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 31,836 | Not disclosed Strike: $17.16 | Not disclosed |
DisclosureSEC source: 0001654954-24-007460 · section16.xml · derivative · entry 3 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,836 shares Expires 2032-12-15 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 32,000 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001654954-24-007460 · section16.xml · derivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2031-10-20 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 1,902 | Not disclosed Strike: $26.88 | Not disclosed |
DisclosureSEC source: 0001654954-24-007460 · section16.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,902 shares Expires 2031-10-11 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:10 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Purchase Warrant · Derivative | 390,000 | Not disclosed Strike: $2.91 | Not disclosed |
DisclosureSEC source: 0001654954-23-004461 · section16.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2026-04-02 F1 · price: The warrant was issued in connection with a private placement and purchase of a promissory note by Mr. Payne in the principal amount of $1,000,000. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 21:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 57 | $2.50 | $142.50 |
DisclosureSEC source: 0001654954-22-016740 · section16.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,401 Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:15 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 191,016 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001654954-22-016735 · section16.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,016 Underlying: Common Stock · 191,016 shares Expires 2032-12-15 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vested immediately upon grant. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 22:39 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 46 | $2.50 | $115.00 |
DisclosureSEC source: 0001654954-22-000864 · section16.xml · nonDerivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 22:39 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 9,122 | $2.50 | $22,805.00 |
DisclosureSEC source: 0001654954-22-000864 · section16.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,298 Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 23:07 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 192,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001654954-21-011337 · section16.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, 25% on each of the next two 4-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| October 12, 2021 Filed Oct 16, 2021 01:20 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 11,416 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001654954-21-011169 · section16.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,416 Underlying: Common Stock · 11,416 shares Expires 2031-10-11 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual General Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| September 30, 2020 Filed Dec 2, 2020 15:51 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001078782-20-000937 · primary_doc.xml · derivative · entry 4 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2025-09-30 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 15:51 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock Purchase Warrant · Derivative | 250,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001078782-20-000937 · primary_doc.xml · derivative · entry 3 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2020-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 15:51 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock | 235,849 | $0.11 | $25,943.39 |
DisclosureSEC source: 0001078782-20-000937 · primary_doc.xml · nonDerivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,151 Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 15:51 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock | 250,000 | $0.10 | $25,000.00 |
DisclosureSEC source: 0001078782-20-000937 · primary_doc.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2019 Filed Apr 8, 2020 19:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001078782-20-000241 · primary_doc.xml · derivative · entry 5 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2024-09-26 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 28, 2018 Filed Apr 8, 2020 19:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.14 | Not disclosed |
DisclosureSEC source: 0001078782-20-000241 · primary_doc.xml · derivative · entry 4 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2023-09-26 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 11, 2017 Filed Apr 8, 2020 19:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.07 | Not disclosed |
DisclosureSEC source: 0001078782-20-000241 · primary_doc.xml · derivative · entry 3 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2022-09-11 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:40 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Disposition to issuerOrdinary Shares | 6,195 | $6.72 | $41,630.40 |
DisclosureSEC source: 0001572426-17-000036 · edgar.xml · nonDerivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John B. Payne Living A/C Disclosed balance after: 0 F1 · price: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to these reported securities. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:40 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Disposition to issuerOrdinary Shares | 10,800 | $6.72 | $72,576.00 |
DisclosureSEC source: 0001572426-17-000036 · edgar.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 13:56 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 3,600 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001171000-17-000058 · edgar.xml · derivative · entry 3 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,600 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 13:56 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 3,600 | $0.13 | $450.00 |
DisclosureSEC source: 0001171000-17-000058 · edgar.xml · nonDerivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2016 Filed Apr 8, 2020 19:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 250,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001078782-20-000241 · primary_doc.xml · derivative · entry 2 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2021-09-10 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 05, 2016 Filed Sep 7, 2016 17:51 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 3,600 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001572426-16-000232 · edgar.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Ordinary Shares · 3,600 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 3,600 of the Restricted Share Units shall vest and become convertible on 7/1/17, subject to payment of the nominal value per share to Issuer within 30 days of vesting. Read SEC document |
| September 10, 2015 Filed Apr 8, 2020 19:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 250,000 | Not disclosed Strike: $0.10 | Not disclosed |
DisclosureSEC source: 0001078782-20-000241 · primary_doc.xml · derivative · entry 1 PAYNE JOHN BERNARD · CIK 0001582392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2020-09-10 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.